vs
Side-by-side financial comparison of Anteris Technologies Global Corp. (AVR) and Bone Biologics Corp (BBLG). Click either name above to swap in a different company.
Anteris Technologies Global Corp. is the larger business by last-quarter revenue ($310.0K vs $255, roughly 1215.7× Bone Biologics Corp). Anteris Technologies Global Corp. runs the higher net margin — -9420.0% vs -339596.1%, a 330176.1% gap on every dollar of revenue.
Anteris Technologies Global Corp is a medical technology firm specializing in innovative structural heart care solutions. It develops and commercializes bioprosthetic heart valves and transcatheter intervention products, serving healthcare providers across North America, Europe, and Asia-Pacific, with core focus on cardiac surgery and interventional cardiology segments.
Bone Biologics Corp is a clinical-stage biotechnology firm focused on developing orthobiologic products to boost bone regeneration and healing for orthopedic surgery patients, including spinal fusion recipients. It mainly operates in the U.S. healthcare market, targeting orthopedic care and regenerative medicine segments.
AVR vs BBLG — Head-to-Head
Income Statement — Q4 2025 vs Q1 2024
| Metric | | |
|---|---|---|
| Revenue | $310.0K | $255 |
| Net Profit | $-29.2M | $-866.0K |
| Gross Margin | 70.6% | — |
| Operating Margin | -9343.5% | -354327.8% |
| Net Margin | -9420.0% | -339596.1% |
| Revenue YoY | — | -54.1% |
| Net Profit YoY | — | 76.7% |
| EPS (diluted) | $-0.74 | $-1.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $310.0K | — | ||
| Q3 25 | $429.0K | — | ||
| Q2 25 | $618.0K | — | ||
| Q1 25 | $556.0K | — | ||
| Q1 24 | — | $255 | ||
| Q4 23 | — | $348 | ||
| Q3 23 | — | $536 | ||
| Q2 23 | — | $428 |
| Q4 25 | $-29.2M | — | ||
| Q3 25 | $-22.2M | — | ||
| Q2 25 | $-20.8M | — | ||
| Q1 25 | $-21.9M | — | ||
| Q1 24 | — | $-866.0K | ||
| Q4 23 | — | $-1.5M | ||
| Q3 23 | — | $-1.9M | ||
| Q2 23 | — | $-1.8M |
| Q4 25 | 70.6% | — | ||
| Q3 25 | 71.3% | — | ||
| Q2 25 | 76.1% | — | ||
| Q1 25 | 62.8% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | -9343.5% | — | ||
| Q3 25 | -5190.0% | — | ||
| Q2 25 | -3379.3% | — | ||
| Q1 25 | -3917.3% | — | ||
| Q1 24 | — | -354327.8% | ||
| Q4 23 | — | -333335.6% | ||
| Q3 23 | — | -388225.7% | ||
| Q2 23 | — | -710249.5% |
| Q4 25 | -9420.0% | — | ||
| Q3 25 | -5185.1% | — | ||
| Q2 25 | -3371.2% | — | ||
| Q1 25 | -3932.4% | — | ||
| Q1 24 | — | -339596.1% | ||
| Q4 23 | — | -445369.3% | ||
| Q3 23 | — | -358154.7% | ||
| Q2 23 | — | -413373.4% |
| Q4 25 | $-0.74 | — | ||
| Q3 25 | $-0.62 | — | ||
| Q2 25 | $-0.58 | — | ||
| Q1 25 | $-0.61 | — | ||
| Q1 24 | — | $-1.31 | ||
| Q4 23 | — | $31.30 | ||
| Q3 23 | — | $-4.90 | ||
| Q2 23 | — | $-5.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $22.0K | — |
| Stockholders' EquityBook value | $-93.0K | $3.7M |
| Total Assets | $23.0M | $3.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $49.0M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $22.0K | — | ||
| Q3 25 | $26.0K | — | ||
| Q2 25 | $30.0K | — | ||
| Q1 25 | $30.0K | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $-93.0K | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $24.4M | — | ||
| Q1 25 | $43.3M | — | ||
| Q1 24 | — | $3.7M | ||
| Q4 23 | — | $2.9M | ||
| Q3 23 | — | $3.8M | ||
| Q2 23 | — | $5.7M |
| Q4 25 | $23.0M | — | ||
| Q3 25 | $19.1M | — | ||
| Q2 25 | $39.9M | — | ||
| Q1 25 | $58.8M | — | ||
| Q1 24 | — | $3.8M | ||
| Q4 23 | — | $3.7M | ||
| Q3 23 | — | $5.0M | ||
| Q2 23 | — | $7.6M |
| Q4 25 | — | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.5M | $-1.3M |
| Free Cash FlowOCF − Capex | $-18.9M | — |
| FCF MarginFCF / Revenue | -6104.5% | — |
| Capex IntensityCapex / Revenue | 128.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-79.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.5M | — | ||
| Q3 25 | $-18.3M | — | ||
| Q2 25 | $-19.5M | — | ||
| Q1 25 | $-21.5M | — | ||
| Q1 24 | — | $-1.3M | ||
| Q4 23 | — | $-2.0M | ||
| Q3 23 | — | $-2.6M | ||
| Q2 23 | — | $-3.6M |
| Q4 25 | $-18.9M | — | ||
| Q3 25 | $-19.0M | — | ||
| Q2 25 | $-20.1M | — | ||
| Q1 25 | $-21.7M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | -6104.5% | — | ||
| Q3 25 | -4434.5% | — | ||
| Q2 25 | -3247.9% | — | ||
| Q1 25 | -3909.5% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | 128.1% | — | ||
| Q3 25 | 180.0% | — | ||
| Q2 25 | 86.9% | — | ||
| Q1 25 | 44.6% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
